会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 64. 发明申请
    • Method of detecting tumor-associated DNA in plasma or serum
    • 检测血浆或血清中肿瘤相关DNA的方法
    • US20110039265A1
    • 2011-02-17
    • US12854039
    • 2010-08-10
    • Christopher D. GockeMichael S. Kopreski
    • Christopher D. GockeMichael S. Kopreski
    • C12Q1/68
    • C07K14/82C07K14/47C07K14/4746C07K2319/00C12Q1/683C12Q1/686C12Q1/6865C12Q1/6886C12Q1/708C12Q2600/112C12Q2600/154C12Q2600/156C12Q2600/16C12Q2535/125
    • This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in human or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such a oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humane and other animals.
    • 本发明涉及在与肿瘤或增生性疾病相关的人或动物血液的血浆或血清部分中检测特异性细胞外核酸。 具体地,本发明涉及来自突变致癌基因或其他肿瘤相关DNA的核酸的检测,以及通过使用快速DNA检测和监测在血浆或血清部分中发现的细胞外突变致癌基因或肿瘤相关DNA的方法 提取后进行核酸扩增,扩增或不扩增突变DNA。 特别地,本发明涉及检测,鉴定或监测人或其他动物中的良性,恶化前或恶性肿瘤的存在,进展或临床状态,其含有通过检测突变的肿瘤与赘生物相关的突变 血浆或血清级分中的肿瘤核酸。 本发明允许检测被认为具有肿瘤或增殖性疾病的人或其他动物的血清或血浆中的细胞外,肿瘤相关核酸,或者在没有任何先前的肿瘤或增殖性疾病的历史或诊断的个体中。 本发明提供了检测源自已知与肿瘤相关的遗传序列的细胞外核酸的能力,例如癌基因,以及先前未被认识为与肿瘤或增殖性疾病相关的遗传序列。 因此,本发明提供了用于早期鉴定结直肠,胰腺,肺,乳腺,膀胱,卵巢,淋巴瘤和携带DNA的肿瘤相关突变的所有其他恶性肿瘤的方法以及用于监测人类和其他动物中的癌症和其他肿瘤性疾病的方法。
    • 68. 发明申请
    • Detection of a Target in a Preservative Solution
    • 在防腐剂溶液中检测靶
    • US20090233269A1
    • 2009-09-17
    • US12408179
    • 2009-03-20
    • James LinderMenashi CohenfordErin CoffmanBrian B. LentrichiaHenrik StenderKenneth Oliveira
    • James LinderMenashi CohenfordErin CoffmanBrian B. LentrichiaHenrik StenderKenneth Oliveira
    • C12Q1/70C12Q1/68
    • C12Q1/6881C12Q1/6841C12Q1/6888C12Q1/708C12Q2525/107
    • This invention relates to methods, articles and compositions useful in detecting target substances in an alcoholic preservative solution, and for identifying sensors useful for binding to such targets. The methods allow for the simultaneous performance of sufficient fixation of a sample and binding of a detectable sensor to a target of interest in the sample. In one aspect, a method is provided that comprises contacting a sample suspected of containing a target with a detectable sensor molecule known to bind to such target in an alcoholic preservative solution. The method maybe performed in multiplex form to permit simultaneous analysis of a plurality of targets. Methods for identifying a sensor capable of binding to a desired target in an alcoholic preservative solution are also provided. An alcoholic preservative solution comprising one or more such detectable sensors is also provided. Also provided is a sample comprising a bound sensor provided by such a process. Also provided are kits useful for such methods.
    • 本发明涉及可用于检测酒精防腐溶液中的目标物质的方法,制品和组合物,以及用于识别用于结合这些靶标的传感器。 所述方法允许同时执行样品的充分固定并将可检测传感器与样品中感兴趣的靶标结合。 在一个方面,提供了一种方法,其包括将怀疑含有靶标的样品与已知结合到该酒精防腐溶液中的该靶标的可检测传感器分子接触。 该方法可以以多路复用形式执行以允许多个目标的同时分析。 还提供了用于鉴定能够结合到酒精防腐剂溶液中所需目标物的传感器的方法。 还提供了包含一种或多种这种可检测传感器的酒精防腐剂溶液。 还提供了包括由这种方法提供的绑定传感器的样本。 还提供了可用于这种方法的试剂盒。
    • 69. 发明申请
    • HPV E6, E7 mRNA ASSAY AND METHODS OF USE THEREOF
    • HPV E6,E7 mRNA测定及其使用方法
    • US20090220945A1
    • 2009-09-03
    • US12391634
    • 2009-02-24
    • Bruce K. Patterson
    • Bruce K. Patterson
    • C12Q1/70
    • C12Q1/708C12Q1/6841C12Q2600/158G06F19/00
    • Provided is an HPV E6, E7 mRNA assay, referenced herein as the “In Cell HPV Assay,” that is capable of sensitive and specific detection of normal cervical cells undergoing malignant transformation as well as abnormal cervical cells with pre-malignant or malignant lesions. The In Cell HPV Assay identifies HPV E6, E7 mRNA via in situ hybridization with oligonucleotides specific for HPV E6, E7 mRNA and quantitates the HPV E6, E7 mRNA via flow cytometry. The In Cell HPV Assay can be carried out in less than three hours directly from liquid-based cervical (“LBC”) cytology specimens. The In Cell HPV Assay provides an efficient and highly sensitive alternative to the Pap smear for determining abnormal cervical cytology.
    • 提供了HPV E6,E7mRNA测定法,其在本文中被称为“In Cell HPV Assay”,其能够敏感和特异性检测经历恶性转化的正常宫颈细胞以及具有恶性前或恶性病变的异常宫颈细胞。 In Cell HPV Assay通过与HPV E6,E7 mRNA特异性寡核苷酸的原位杂交鉴定HPV E6,E7 mRNA,并通过流式细胞术定量HPV E6,E7 mRNA。 In Cell HPV Assay可以在不到三个小时的时间内直接从液体宫颈(“LBC”)细胞学标本中进行。 In Cell HPV Assay提供了一种有效和高度敏感的替代方法,用于确定宫颈细胞学异常的Pap涂片。
    • 70. 发明授权
    • Methods for selecting monoclonal antibody therapies using extracellular DNA
    • 使用细胞外DNA选择单克隆抗体疗法的方法
    • US07569349B2
    • 2009-08-04
    • US11739477
    • 2007-04-24
    • Christopher D. GockeMichael S. KopreskiFloyd A. Benko
    • Christopher D. GockeMichael S. KopreskiFloyd A. Benko
    • C12Q1/68C12P19/34
    • C07K14/82C07K14/47C07K14/4746C07K2319/00C12Q1/683C12Q1/686C12Q1/6865C12Q1/6886C12Q1/708C12Q2600/112C12Q2600/154C12Q2600/156C12Q2600/16C12Q2535/125
    • This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals.
    • 本发明涉及在与肿瘤或增生性疾病相关的人或动物血液的血浆或血清部分中检测特异性细胞外核酸。 具体地,本发明涉及来自突变致癌基因或其他肿瘤相关DNA的核酸的检测,以及通过使用快速DNA检测和监测在血浆或血清部分中发现的细胞外突变致癌基因或肿瘤相关DNA的方法 提取后进行核酸扩增,扩增或不扩增突变DNA。 特别地,本发明涉及通过检测突变体的检测,鉴定或监测包含与赘生物相关的突变的人或其他动物中的良性,恶化前或恶性肿瘤的存在,进展或临床状态 血浆或血清级分中的肿瘤核酸。 本发明允许检测被认为具有肿瘤或增殖性疾病的人或其他动物的血清或血浆中的细胞外,肿瘤相关核酸,或者在没有任何先前的肿瘤或增殖性疾病的历史或诊断的个体中。 本发明提供了检测源自已知与肿瘤形成相关的遗传序列的细胞外核酸的能力,例如癌基因,以及先前未被认识为与肿瘤或增殖性疾病相关的遗传序列。 因此,本发明提供了用于早期鉴定结直肠,胰腺,肺,乳腺,膀胱,卵巢,淋巴瘤和携带DNA的肿瘤相关突变的所有其他恶性肿瘤的方法以及用于监测人和其他动物中的癌症和其他肿瘤性疾病的方法。